1. Home
  2. DXYZ vs MAZE Comparison

DXYZ vs MAZE Comparison

Compare DXYZ & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DXYZ
  • MAZE
  • Stock Information
  • Founded
  • DXYZ N/A
  • MAZE 2018
  • Country
  • DXYZ
  • MAZE United States
  • Employees
  • DXYZ N/A
  • MAZE N/A
  • Industry
  • DXYZ
  • MAZE
  • Sector
  • DXYZ
  • MAZE
  • Exchange
  • DXYZ Nasdaq
  • MAZE NYSE
  • Market Cap
  • DXYZ 413.3M
  • MAZE 367.0M
  • IPO Year
  • DXYZ 2024
  • MAZE 2025
  • Fundamental
  • Price
  • DXYZ $37.46
  • MAZE $11.94
  • Analyst Decision
  • DXYZ
  • MAZE Strong Buy
  • Analyst Count
  • DXYZ 0
  • MAZE 3
  • Target Price
  • DXYZ N/A
  • MAZE $25.67
  • AVG Volume (30 Days)
  • DXYZ N/A
  • MAZE 100.7K
  • Earning Date
  • DXYZ N/A
  • MAZE 08-14-2025
  • Dividend Yield
  • DXYZ N/A
  • MAZE N/A
  • EPS Growth
  • DXYZ N/A
  • MAZE N/A
  • EPS
  • DXYZ N/A
  • MAZE 0.34
  • Revenue
  • DXYZ N/A
  • MAZE $167,500,000.00
  • Revenue This Year
  • DXYZ N/A
  • MAZE N/A
  • Revenue Next Year
  • DXYZ N/A
  • MAZE N/A
  • P/E Ratio
  • DXYZ N/A
  • MAZE $35.77
  • Revenue Growth
  • DXYZ N/A
  • MAZE N/A
  • 52 Week Low
  • DXYZ N/A
  • MAZE $6.71
  • 52 Week High
  • DXYZ N/A
  • MAZE $17.00
  • Technical
  • Relative Strength Index (RSI)
  • DXYZ N/A
  • MAZE N/A
  • Support Level
  • DXYZ N/A
  • MAZE N/A
  • Resistance Level
  • DXYZ N/A
  • MAZE N/A
  • Average True Range (ATR)
  • DXYZ 0.00
  • MAZE 0.00
  • MACD
  • DXYZ 0.00
  • MAZE 0.00
  • Stochastic Oscillator
  • DXYZ 0.00
  • MAZE 0.00

About DXYZ Destiny Tech100 Inc. Common Stock

Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.

About MAZE MAZE THERAPEUTICS INC

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Share on Social Networks: